



Providing state-of-the-art HIV education, consultation, and resource materials to healthcare professionals throughout the region.

- Chart Reviews, Clinical Consultation, F/C AETC - Project ECHO®, HIV CareLink Newsletter, HIV Updates, Preceptorships, Treatment Guideline Resources, Web-Based Education

www.FCAETC.org 866.FLC.AETC (866.352.2382)

Clinical Consultation Services

www.FCAETC.org/consultation Available to clinicians in Florida, Puerto Rico, and the U.S. Virgin Islands

Online Consultation Consultation on the diagnosis, prevention, and treatment of HIV/AIDS and related conditions

Resistance Testing Consultation Consultation on the interpretation of resistance test results

-- If outside our region, please consult the national services below --

National Consultation Services

Clinician Consultation Center

Online Consultation: nccc.ucsf.edu

Pre-Exposure Prophylaxis 855.448.7737 Advice to clinicians on providing antiretroviral drug therapy to HIV uninfected persons to prevent HIV infection

Post-Exposure Prophylaxis 888.448.4911 Timely answers for urgent exposure management

Perinatal HIV/AIDS 888.448.8765 Rapid perinatal HIV consultation

HIV/AIDS Management 800.933.3413 Peer-to-peer advice on HIV/AIDS management



www.USFCenter.org



ARV Therapy in Adults & Adolescents

July 2015

Editors: Jeffrey Beal, MD, AAHIVS; Maribel Gonzalez, MSN, ARNP; Jennifer Janelle, MD, AAHIVS; Joanne J. Orrick, PharmD, AAHIVP

Managing Editor: Kimberly Tucker, MEd; Layout: Adrian Green, BS

This resource summarizes information from the Department of Health and Human Services (DHHS) guidelines referenced below. Critical information regarding antiretroviral agents currently approved for use in adults and adolescents is included.

Unless otherwise noted, information is adapted from the Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.

Fact Sheet: Pharmaceutical Company Co-payment Assistance Programs (CAP)

This fact sheet from the National Alliance of State & Territorial AIDS Directors (NASTAD) provides background on what co-payment assistance programs are and an overview of CAP contact information, drugs covered, and assistance offered.

SPECIAL THANKS TO:

Colorado AIDS Education and Training Center for medication images

www.AIDSmeds.com for phonetic pronunciations

FIND US ON THE WEB

www.FCAETC.org

Facebook, Twitter, YouTube, LinkedIn icons and FCAETC text

An up-to-date and downloadable PDF file is available online at www.FCAETC.org/treatment

Regimens for Treatment of HIV-1 in Antiretroviral-Naive Patients

Regimens below assume no baseline resistance. Resistance testing recommended for all pts upon entry into care and prior to starting ARVs.

Table with columns for Regimen Options, INSTI-Based, PI-Based, NNRTI-Based, and Alternative Regimen Options. Lists various drug combinations like Dolutegravir + abacavir + lamivudine, etc.

- 1. See Table 2 of DHHS guidelines for rating scheme for strength of recommendations/quality of evidence. 2. Emtricitabine may replace lamivudine and vice versa (co-formulation is major determining factor).

The information contained in this publication is intended for medical professionals, as a quick reference to the national guidelines. This resource does not replace nor represent the comprehensive nature of the published guidelines.

Visit www.FCAETC.org/treatment for the most up-to-date version of this resource.

This publication is made possible by AETC grant award H44HA00049 from the HIV/AIDS Bureau (HAB) of the Health Resources Services Administration (HRSA), U.S. Department of Health and Human Services (HHS).

Renal Dose Adjustments

Please visit: www.kidney.org/professionals/kdoqi/gfr_calculator.cfm for a glomerular filtration rate calculator to estimate renal function.

Table with columns for Agent(s) and Dose Adjustment. Lists drugs like Zidovudine, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, NNRTIs, PIs, INSTI, CCR5 Inhibitor, and Pharmacokinetic Enhancers.

Renal Dosing for Combo Products

Table with columns for Agent(s) and Dose Adjustment. Lists combinations like EFV/FTC/TDF, ZDV/3TC, ABC/3TC, etc.

Hepatic Dosing of ARVs

See DHHS Guidelines (Appendix B, Table 7) for recommendations for dosing ARVs in pts with hepatic insufficiency.

Child-Pugh (CP) Score Calculation

Table for Child-Pugh Score Calculation with columns for Score, Encephalopathy, Ascites, Albumin, Total Bilirubin, Modified Total Bilirubin, Prothrombin Time, and INR.

- 10. Class A: Score 5-6; Class B: Score 7-9; Class C: Score > 9. 11. Grade 1: mild confusion, anxiety, restlessness, fine tremor, slowed coordination; Grade 2: drowsiness, disorientation, asterixis; Grade 3: somnolent but rousable, marked confusion, incoherent speech, incontinent, hyperventilation; Grade 4: coma, decerebrate posturing, flaccidity.

ARV Components Not Recommended as Part of Initial Therapy

Table with columns for Agent(s), Comments, Agent(s), and Comments. Lists drugs like ABC/ZDV/3TC, d4T + 3TC, ddI + (3TC or FTC), ZDV/3TC, DLV, ETR, NVP, etc.

Antiretroviral Regimens or Components Not Recommended at Any Time

Table with columns for Regimens/Components and Comments. Lists regimens like Monotherapy (All), Dual-NNRTI (All), Dual-NRTI (All), Triple NRTI (All) exceptions, d4T + ZDV (All), d4T + ddI (All), FTC + 3TC (All), etc.

- 13. The Guidelines list as "not recommended as part of initial therapy" but the F/C AETC medical editors do not recommend at any time.

Statin Interactions with ARVs

NOTE: Interactions with indinavir and nelfinavir are not included since these are rarely used

Table with columns for Statin, Interacting PI(s), and Prescribing Recommendation. Lists statins like Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin and their interactions with ARVs.

14. See DHHS Guidelines (Table 19b) for statin interaction with NNRTIs. Generally no dosage adjustments needed but there may be decreased statin response depending on agents used.

NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)

Class adverse effects: Lactic acidosis and hepatic steatosis

Abacavir (Ziagen®, ABC)

(uh-BACK-ah-veer) G, H, C icons. Dosage form: 300 mg tab, 20 mg/mL soln (240 mL/bottle). Also available in combination products: Epzicom®, Trizivir®, Triumeq®.



